You are here

  • Home
  • Archive
  • Volume 18, Issue 2
  • Among statin-treated patients, LDL, non-HDL and apoB cholesterol biomarkers were associated with increased risks of cardiovascular events

Article Text

Article menu
Download PDFPDF
Prevention
Systematic review with meta-analysis
Among statin-treated patients, LDL, non-HDL and apoB cholesterol biomarkers were associated with increased risks of cardiovascular events
  1. Allan David Sniderman,
  2. George Thanassoulis
  1. Department of Medicine/Cardiology, McGill University, Montreal, Quebec, Canada
  1. Correspondence to: Allan David Sniderman
    , Department of Medicine/Cardiology, McGill University, Royal Victoria Hospital, 687 Pine Avenue West, Room H7.22, Montreal, Quebec, Canada H3A 1A1; allansniderman{at}hotmail.com

https://doi.org/10.1136/eb-2012-100787

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012;307:1302–9.OpenUrlCrossRefPubMedWeb of Science

    Context

    Each very-low-density lipoprotein and low-density lipoprotein (LDL) particle contains one molecule of apolipoprotein B (apoB). Increased numbers of cholesterol-depleted LDL particles are common in patients with hypertriglyceridaemia, premature vascular disease, obesity and type-2 diabetes mellitus and much in vitro and in vivo evidence indicates cholesterol-depleted LDL particles are at least as atherogenic as larger, more cholesterol-replete LDL particles.1 Nevertheless, …

    View Full Text

    Footnotes

    • Competing interests None.